Yuqing Huo | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Yuqing Huo | Cardiovascular Pharmacology | Best Researcher Award

Baylor College of Medicine | United States

Prof. Yuqing Huo, Ph.D., is a distinguished cardiovascular and vascular biology researcher whose work bridges molecular mechanisms and clinical applications in inflammation, angiogenesis, and metabolic disease. A U.S. citizen with an extensive background in biomedical science, he currently serves as Professor and Danny B. Jones Chair at the Department of Ophthalmology, Department of Medicine/Section of Cardiovascular Research, and Department of Molecular and Cellular Biology at Baylor College of Medicine in Houston, Texas. His academic journey has been defined by a lifelong dedication to understanding vascular inflammation, endothelial function, and cellular metabolism in cardiovascular and ocular diseases.Prof. Huo earned his Medical Degree from Jining Medical College, followed by a Master’s in Cardiology from Qingdao University and a Doctoral Degree in Molecular Cardiology from Beijing Medical University. He further advanced his expertise as a Postdoctoral Research Associate in Inflammation and Vascular Biology at the University of Virginia, where he worked in Dr. Klaus Ley’s renowned laboratory at the Cardiovascular Research Center. His postdoctoral research laid the foundation for his later breakthroughs in vascular inflammation, monocyte recruitment, and endothelial interactions in atherosclerosis.Over his distinguished academic career, Prof. Huo has held faculty positions at several leading institutions, including the University of Virginia, the University of Minnesota, and Augusta University, where he served as Professor, Chief of the Vascular Inflammation Program, and Director of the Vision Discovery Institute. His leadership in the field has shaped numerous interdisciplinary programs that integrate cardiovascular and ocular research, expanding the understanding of inflammation and angiogenesis in chronic diseases.His scientific achievements have been widely recognized through numerous honors and awards, including distinctions from the American Heart Association, the American Physiological Society, and the American Diabetes Association. His accolades include the New Investigator Award, Young Investigator Award, and several institutional honors for outstanding research contributions and academic excellence.Prof. Huo’s active research focuses on “Myeloid glycolysis in pathological ocular angiogenesis,” “Myeloid PFKFB3 in subretinal fibrosis,” “Adenosine receptor 2A in subretinal fibrosis,” and “VSMC PFKFB3 in atherogenesis,” among others. His projects, supported by the National Institutes of Health (NIH) and the American Heart Association (AHA), aim to uncover novel molecular targets that regulate inflammation, fibrosis, and vascular remodeling. Through the use of genetically engineered models and molecular approaches, his research explores glycolytic reprogramming in immune cells and vascular tissues, paving the way for innovative therapeutic strategies in cardiovascular, metabolic, and ocular disorders.

Profile: Google Scholar

Featured Publications

Cheng, Y., Liu, X., Yang, J., Lin, Y., Xu, D. Z., Lu, Q., Deitch, E. A., Huo, Y., Delphin, E. S., & Zhang, C. (2009). MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circulation Research, 105(2), 158–166.

Huo, Y., Hafezi-Moghadam, A., & Ley, K. (2000). Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circulation Research, 87(2), 153–159.

Huo, Y., Schober, A., Forlow, S. B., Smith, D. F., Hyman, M. C., Jung, S., Littman, D. R., Weber, C., & Ley, K. F. (2003). Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Medicine, 9(1), 61–67.

Luo, X., Li, H., Ma, L., Zhou, J., Guo, X., Woo, S. L., Pei, Y., Knight, L. R., Deveau, M., Yang, S., & Huo, Y. (2018). Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. Gastroenterology, 155(6), 1971–1984.e4.

Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, D. C., & Liao, J. K. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 285(5431), 1276–1279.

Ramos, C. L., Huo, Y., Jung, U., Ghosh, S., Manka, D. R., Sarembock, I. J., & Ley, K. (1999). Direct demonstration of P-selectin– and VCAM-1–dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E–deficient mice. Circulation Research, 84(11), 1237–1244.

Feng Jiang | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Feng Jiang | Cardiovascular Pharmacology | Best Researcher Award

Stanford University | United States

Dr. Feng Jiang is a highly accomplished postdoctoral researcher at Stanford University, specializing in uncovering the mechanisms and risk factors of human autoimmune diseases. His research focuses on performing experiments and bioinformatic analyses on genetic and RNA-seq data to identify key disease mechanisms and develop therapeutics targeting these pathways. He has also established predictive models based on risk factors to enable early diagnosis of autoimmune conditions. Prior to his postdoctoral work, Dr. Jiang completed his Ph.D. at the University of Rochester, where he conducted extensive research targeting profibrotic genes to combat cardiac fibrosis. His work involved identifying common regulators controlling the expression of profibrotic genes, inhibiting their activity in animal models, and exploring the regulation of mRNA translation in cancer and heart disease. Additionally, he investigated the role of microRNAs in disease, identifying key microRNAs involved in disease progression and their potential as biomarkers for diagnosis and monitoring.Dr. Jiang also gained international research experience as a research fellow at Yat-sen University, where he executed sequencing library construction and established analysis pipelines for human and mouse samples. During his undergraduate studies at Wuhan University, he investigated the role of the gene GLIS2 in cancer progression using CRISPR/Cas9 gene editing techniques.He has contributed significantly to the scientific literature with numerous impactful publications, including works such as RNA Binding Protein PRRC2B Mediates Translation of Specific mRNAs and Regulates Cell Cycle Progression, Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis, Mammalian RNA Switches: Molecular Rheostats in Gene Regulation, Disease, and Medicine, MicroRNA574 Regulates FAM210A Expression and Influences Pathological Cardiac Remodeling, Correlation Between Severity of Spinal Stenosis and Multifidus Atrophy in Degenerative Lumbar Spinal Stenosis, Usage of Procalcitonin and sCD14-ST as Diagnostic Markers for Postoperative Spinal Infection, Correlations Between Serum P2X7, Vitamin A, 25-Hydroxy Vitamin D, and Mycoplasma Pneumoniae Pneumonia, Disruption of Tdrd5 Decouples the Stepwise Processing of Long Precursor Transcripts During Pachytene PIWI-Interacting RNA Biogenesis, and Cardiomyocyte-Specific Loss of Glutamyl-Prolyl-tRNA Synthetase Leads to Disturbed Protein Homeostasis and Dilated Cardiomyopathy.

Profile: Google Scholar

Featured Publications

Jiang, F., Hedaya, O. M., Khor, E. S., Wu, J., Auguste, M., & Yao, P. (n.d.). RNA binding protein PRRC2B mediates translation of specific mRNAs and regulates cell cycle progression. Nucleic Acids Research.

Wu, J., Subbaiah, K. C. V., Xie, L. H., Jiang, F., Khor, E. S., Mickelsen, D., Myers, J. R., Tang, W. H. W., & Yao, P. (n.d.). Glutamyl-prolyl-tRNA synthetase regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. Circulation Research.

Wu, J., Subbaiah, K. C. V., Jiang, F., Hedaya, O., Mohan, A., Yang, T., Welle, K., Ghaemmaghami, S., Tang, W. H. W., Small, E., Yan, C., & Yao, P. (n.d.). MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodeling. EMBO Molecular Medicine.

Subbaiah, K. C. V., Hedaya, O., Wu, J., Jiang, F., & Yao, P. (n.d.). Mammalian RNA switches: Molecular rheostats in gene regulation, disease, and medicine. Computational and Structural Biotechnology Journal.

Hedaya, O. M., Venkata Subbaiah, K. C., Jiang, F., Xie, L. H., Wu, J., Khor, E. S., Zhu, M., Mathews, D. H., Proschel, C., & Yao, P. (n.d.). Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy. Nature Communications.

Xia, G., Li, X., Shang, Y., Fu, B., Jiang, F., Liu, H., & Qiao, Y. (n.d.). Correlation between severity of spinal stenosis and multifidus atrophy in degenerative lumbar spinal stenosis. BMC Musculoskeletal Disorders.

Zhu, X., Li, K., Zheng, J., Xia, G., Jiang, F., Liu, H., & Shi, J. (n.d.). Usage of procalcitonin and sCD14-ST as diagnostic markers for postoperative spinal infection. Journal of Orthopaedics and Traumatology.

Li, W., Li, Y., Jiang, F., & Liu, H. (n.d.). Correlation between serum levels of microRNA-21 and inflammatory factors in patients with chronic heart failure. Medicine.